Device Trial Radar · NCT07031492
Relieving Carb Counting Via Flexible-userinteraction Multiple-input Control Architectures
Last checked: Nov 19, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universitat Politècnica de València
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Developing algorithms for Automated Insulin Delivery (AID) systems that alleviate the burden of meal announcements, culminating in the FLEX-AP system. This fully automated artificial pancreas system is designed to operate without meal or exercise announcements while allowing for optional user input. FLEX-APaims to achieve a balance between glycemic control and user quality of life by incorporating user preferences into its operation. The FLEX-AP system features a flexible control architecture tailored to handle unannounced meals and exercise. It also allows for optional meal announcements and offers guidance for mitigating hypoglycemia, such as counterregulatory actions like rescue carbohydrate intake for patients who prefer it. The proposed benefit of FLEX-AP is to improve glycemic control while respecting individual preferences, which sets it apart from existing AID systems.
Conditions
- T1DM - Type 1 Diabetes Mellitus
Interventions
FLEX-AP system will be implemented to T1D patientsDevice
A FLEX-AP system will be implemented to T1D patients after they have been given a Minimed 780G hybrid closed-loop system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of the FLEX-AP systemTime frame: 4 weeks
- Safety of the FLEX-AP systemTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.